Search
Now showing items 1-8 of 8
Design and synthesis of bifunctional molecules for directing phosphorylation
(Institute of Cancer Research (University Of London), 2023-05-04)
The field of bifunctional molecules such as PROTAC, DUBTAC and PhoRC has demonstrated that inducing proximity between two protein complexes is sufficient to redirect post-translational modifications (PTMs), and effect ...
Investigating the diverse cellular functions of APOBEC3A and APOBEC3B in urothelial carcinoma
(Institute of Cancer Research (University Of London), 2023-02-20)
Urothelial carcinoma (UCC) is characterised by a high mutational burden, with many of the identified mutations resulting from the mutagenic activity of the APOBEC3 (A3) family of cytidine deaminases. A3B expression is ...
Molecular profiling of cell free DNA in patients with paediatric solid tumours
(Institute of Cancer Research (University Of London), 2023-05-02)
Tumour tissue profiling studies show that a substantial proportion of paediatric cancer patients have potentially actionable alterations and minimally invasive molecular profiling test using cell free DNA (cfDNA) could ...
Harnessing the power of cryo electron microscopy to visualise a full-length kinesin KIFC1 (HSET)
(Institute of Cancer Research (University Of London), 2023-05-30)
Cancer cells are known to exhibit a phenomenon typically known as centrosome amplification (CA), which is responsible for multipolar spindle formation during mitosis. This severely impairs cytokinesis and could hence prove ...
Unravelling the mechanisms of acquired immunomodulatory drug resistance in multiple myeloma
(Institute of Cancer Research (University Of London), 2023-12-01)
Immunomodulatory drugs (IMiDs) are a cornerstone of multiple myeloma
treatment and newer cereblon E3 ligase modulating drugs (CELMoDs) are in
clinical trials. However, a major barrier to improving patient outcomes is ...
Developing RAS-binding antibody-derived hit compounds
(Institute of Cancer Research (University Of London), 2023-09-27)
Exploring an oncolytic virus triggered PD-L1 response via immunoPET
(Institute of Cancer Research (University Of London), 2023-01-23)
Oncolytic virotherapy (OV) exploits viruses which preferentially infect and kill cancerous cells. Moreover, oncolytic viruses stimulate the tumour-immune microenvironment towards an inflammatory phenotype. Therefore, OV ...
Lysine-targeting covalent inhibitors
(Institute of Cancer Research (University Of London), 2023-12-14)
Targeted Covalent Inhibitors (TCIs) represent an increasingly important strategy in modern drug discovery. TCIs exploit high affinity, reversible ligands which are then modified with modestly-reactive electrophilic warheads ...